logo
Share SHARE
FONT-SIZE Plus   Neg

Halozyme Q1 Loss Widens - Quick Facts

Halozyme Therapeutics, Inc. (HALO) Monday reported a first-quarter loss of $15.1 million or $0.14 per share, which widened from $9.6 million or $0.10 per share in the year-ago period.

On average, eight analysts polled by Thomson Reuters expected the company to report a loss of $0.11 per share for the first quarter. Analysts' estimates typically exclude special items.

First-quarter revenues declined to $7.4 million from $7.5 million last year. Analysts expected revenues of $7.31 million for the quarter.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Rare commodities are worth more than good is a Chinese adage. And more so when it is in the sought-after drug space. Rare and ultra-rare diseases, also called orphan and ultra-orphan diseases, as the names imply, affect very small numbers of patients. So why the clamor? Shares of steel giant ArcelorMittal were losing around 4 percent in the early morning trading in Amsterdam after the company reported sharp decline in first-quarter EBITDA, a key earnings metric, as sales were weak with lower prices and production. Net loss, however, narrowed from last year. The company also confirmed its forecast for annual EBITDA, which is lower than last year. As the din settles down on a dismal quarter at one of the world's exciting tech company, it is time to sit back and take stock of what went wrong and will the wrong be righted in the near term?
comments powered by Disqus
Follow RTT